New Gout Treatment Offered by AAIR

Posted on: 10/06/2011

Krystexxa is an intravenous (IV) drug for the treatment of chronic gout in adult patients that is shown to improve outcomes for those who have failed on other conventional gout therapies. Krystexxa must be administered intravenously in a health care setting by qualified medical providers every 2 weeks.  Starting in October 2011 Krystexxa will be available in the AAIR infusion center for those patients prescribed this medication by their physician. For more information call one of the nurses in the AAIR infusion center at 442-0150, extension 175.

Back to articles